Linagliptin
CAS:668270-12-0
Molecular formula:C25H28N8O2
Molecular weight:472.54
Product description:Linagliptin (BI-1356, trade names Tradjenta and Trajenta) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.
Linagliptin (once-daily) was approved by the U.S. Food and Drug Administration (FDA) on 2 May 2011 for treatment of type II diabetes.
For more information OR other specifications of the products, please contact us.
Send Enquiry Online
For more information OR other products. Please contact us by Email, Tel or Send online enquiry. We will reply you as soon as possible.
1. E-mail: se(at)serebiomedical.com
2. Tel: +1 571 572 9408
3. WhatsApp: +1 571 572 9408
If you are interested in our product, want to know more about product information, please contact us, we are professional products manufacturers, our price concessions, professional level produce things cheap beauty products, welcomed the consultation.
